Appili Therapeutics to present progress on Tularemia vaccine

Appili Therapeutics (APLIF) announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, will participate in the NATO Chemical, Biological, Radiological and Nuclear Conference, taking place September 8-10, 2025, in Switzerland. Dr. Gelhaus will join NATO and allied representatives and present an update on Appili’s biodefense vaccine program, highlighting ATI-1701, the company’s potential first-in-class vaccine candidate designed to prevent infection by Francisella tularensis, the causative agent of tularemia. The presentation will offer an in-depth overview of the tularemia threat to military and civilian populations and underscore the potential of ATI-1701 to address this critical gap in biodefense preparedness. The presentation will highlight preclinical data and ongoing development of ATI-1701, which has been supported in part by a cooperative agreement award from the USAFA. Francisella tularensis is a highly infectious pathogen capable of causing severe illness and death and is designated a top-priority biothreat. Medical countermeasures against this agent remain a key biodefense priority for the United States and governments around the world.